Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin in Adults With Fontan Circulatory Failure
NCT06955260Phase 3Recruiting
- Start
- May 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Fontan circulatory failure (FCF) comparing Empagliflozin with Placebo (2 arms). Primary endpoint: Hierarchical endpoint at 12 weeks. Started May 2026; status: recruiting.
02
Drugs
empagliflozin
03
Conditions
Fontan circulatory failure (FCF)
Beyond the preview
Go deeper on NCT06955260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06955260.